Int J Clin Health Psycho:创伤后应激障碍和执行功能损伤的共存模式

2019-09-28 王力研究组 中科院心理所

创伤后应激障碍(Posttraumatic stress disorder,PTSD)与执行功能损伤(Executive dysfunction,ED)均是个体经历创伤应激事件后常见的负性心理反应。理解这二者的关系对解释PTSD的心理病理过程和开发有效针对于PTSD的干预手段都具有十分重要的意义。因此这一问题近年来已经得到了越来越多研究者的关注。尽管目前已经发表了大量关于二者关系的研究,但研究结果

创伤后应激障碍(Posttraumatic stress disorder,PTSD)与执行功能损伤(Executive dysfunction,ED)均是个体经历创伤应激事件后常见的负性心理反应。理解这二者的关系对解释PTSD的心理病理过程和开发有效针对于PTSD的干预手段都具有十分重要的意义。因此这一问题近年来已经得到了越来越多研究者的关注。尽管目前已经发表了大量关于二者关系的研究,但研究结果的异质性却很高。目前已有的16项研究比较了PTSD患者和健康对照中的执行功能损伤情况,其中仅有9项研究发现了PTSD患者具有更严重的执行功能损伤。

这种研究结果的高度不一致可能是由于不同研究采取了不同的执行功能测量工具造成的。已有的研究都是通过神经心理学测验对执行功能进行测量,主要包括连线测试(TMT)、,威斯康辛卡片测验(WSCT)、,Stroop测验等。但是神经心理学测验的生态效度一直受到质疑。执行功能自评问卷(DEX-S)是一个测量执行功能损伤的量表式工具,具有出色的生态效度,能够很好测量日常生活中的执行功能损伤症状,并涵盖了执行功能不同维度的损伤情况。因此,采用DSX-S测量执行功能损伤为探究PTSD和执行功能损伤提供了一个更好的方法。

此外需要注意的是,前人的研究大多采用变量中心的研究取向来探讨两者之间的关系,忽视了个体之间的显著差异。因此,研究者很有必要从群体异质性的角度,采用以人为中心的研究取向,如潜在剖面分析(Latent profile analysis,LPA)来进行探讨。该研究取向能够识别出具有相同合并模式的亚群体,有助于人们更好地理解PTSD与执行功能损伤之间的关系。

针对研究现状,中国科学院心理健康重点实验室王力研究组采用LPA的方法对13438名儿童青少年地震幸存者的PTSD与执行功能损伤进行了分析。

结果显示最优拟合模型由低症状(36.8%)、中等症状(37.8%)、高症状(21.7%)和特高症状组(3.7%)4种平行的症状合并模式构成(见图1);年龄、性别、民族等人口统计学变量及地震相关的创伤暴露、生活质量与不同合并模式存在特异性或一致性的关联。



图1 不同时间点PTSD总体症状严重程度与5-HTTLPR基因型的关联

本研究是首个对PTSD和执行功能损伤症状合并模式的研究。研究结果表明PTSD和执行功能损伤的关系稳定存在,不受个体差异的影响。

这一结果一方面为进一步从理论上阐释PTSD与认知功能损伤的关系提供了重要基础,同时也提示了在对PTSD症状较为严重的患者进行干预时需要考虑到其执行功能的损伤情况,采取对执行功能依赖更小的干预方案,如药物干预。

本研究受到国家自然科学基金项目(31271099,31471004)、教育部人文社会科学重点研究基地项目(16JJD190006),中国科学院对外合作项目(153111KYSB20160036),中国科学院重点部署项目(ZDRW-XH-2019-4)及北京市科学技术委员会(Z171100000117014)的支持。

原始出处:
Li, G., Wang, L., Cao, C., Fang, R., et al. Posttraumatic Stress Disorder and executive dysfunction among children and adolescents: A Latent Profile Analysis. International Journal of Clinical and Health Psychology, 2019, 19(3), 228–236.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1861340, encodeId=218818613409a, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jul 08 11:13:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335275, encodeId=81ed13352e541, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397838, encodeId=8edb139e8383c, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445297, encodeId=ce60144529e3f, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621817, encodeId=bc51162181e85, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2020-07-08 shizhenshan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1861340, encodeId=218818613409a, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jul 08 11:13:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335275, encodeId=81ed13352e541, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397838, encodeId=8edb139e8383c, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445297, encodeId=ce60144529e3f, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621817, encodeId=bc51162181e85, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1861340, encodeId=218818613409a, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jul 08 11:13:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335275, encodeId=81ed13352e541, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397838, encodeId=8edb139e8383c, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445297, encodeId=ce60144529e3f, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621817, encodeId=bc51162181e85, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1861340, encodeId=218818613409a, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jul 08 11:13:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335275, encodeId=81ed13352e541, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397838, encodeId=8edb139e8383c, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445297, encodeId=ce60144529e3f, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621817, encodeId=bc51162181e85, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1861340, encodeId=218818613409a, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jul 08 11:13:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335275, encodeId=81ed13352e541, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397838, encodeId=8edb139e8383c, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445297, encodeId=ce60144529e3f, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621817, encodeId=bc51162181e85, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Sep 29 23:13:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]

相关资讯

研究发现18岁以下青少年中有8%患有创伤后应激障碍

发表在"柳叶刀精神病学 "(The Lancet Psychiatry)一项新研究显示,有十三分之一的18岁以下青少年患有创伤后应激障碍(PTSD)。

Aust N Z J Psychiatry:发现创伤后应激障碍高危患者潜在影像学标志

近日,上海交通大学医学院附属精神卫生中心王振研究团队与附属仁济医院影像科合作在Australian & New Zealand Journal of Psychiatry杂志在线发表题为Cortical surface area reduction in identification of subjects at high risk for post-traumatic stress disord

三重再摄取抑制剂(TRI)TNX-1600治疗创伤后应激障碍

Tonix是一家临床阶段的生物制药公司,Tonix近日宣布,将扩大三重再摄取抑制剂(TRI)TNX-1600的适应症范围,以治疗创伤后应激障碍(PTSD)和潜在的其他中枢神经系统(CNS)疾病。

Psychoneuroendocrinology:中科院心理所发现促食欲激素系统影响创伤后应激障碍症状

促食欲激素是指一类能够调节促进食欲的激素。日前,中国科学院心理研究所科研团队首次发现了促食欲激素系统对创伤后应激障碍症状的影响。相关研究成果已经发表于国际心理神经内分泌学会会刊。

J Child Psychol Psyc:儿童创伤后应激障碍不容忽视

患有创伤后应激障碍(PTSD)的儿童和青少年可以只用几个小时的EMDR或认知行为写作治疗(CBWT)就成功治疗。这是阿姆斯特丹大学(UVA)和儿童和青年创伤中心(GGZ Rivierduinen)的一项新研究发现。这篇论文于6月29日星期四发表在《儿童心理学与精神病学杂志》上。

Tonix停止对Tonmya进行军事相关创伤后应激障碍(PTSD)的后期研究

Tonix制药表示正停止对Tonmya(一种舌下含服的环苯扎林片状透明胶囊制剂)进行III期HONOR研究,Tonmya起初用于治疗军事相关的创伤后应激障碍(PTSD)。根据Tonix的说法,一项中期分析显示,在第12周,主要终点与安慰剂分离不足。